Vitamin D Supplements Market by Ingredient Source (Cholecalciferol, Ergocalciferol), Form (Capsule, Gummy, Liquid), End User, Application, Distribution Channel - Global Forecast 2025-2032
Description
The Vitamin D Supplements Market was valued at USD 1.54 billion in 2024 and is projected to grow to USD 1.69 billion in 2025, with a CAGR of 9.71%, reaching USD 3.23 billion by 2032.
A concise integrated overview of supply chain, consumer dynamics, regulatory shifts, and product innovation shaping strategic planning for vitamin D supplements
This executive summary synthesizes contemporary dynamics shaping the vitamin D supplements landscape to equip senior leaders with contextually relevant intelligence and actionable perspective. It draws together supply chain trends, regulatory developments, consumer behavior shifts, and distribution innovations that converge to influence product development, go-to-market approaches, and procurement priorities. The aim is to provide a succinct, integrated briefing that supports cross-functional planning across R&D, commercial strategy, and operations.
The narrative foregrounds the interplay of scientific validation, ingredient sourcing decisions, and evolving consumption formats, while recognizing the importance of regulatory clarity and trade flows. By emphasizing implications rather than raw metrics, the summary anticipates near-term strategic choices and highlights priority areas for deeper analysis. Readers should be able to translate the insights into concrete next steps for portfolio refinement, channel optimization, and stakeholder engagement.
How scientific validation, consumer preference evolution, and omnichannel distribution convergence are reshaping product formulation and go-to-market approaches in vitamin D supplements
The vitamin D supplements arena is undergoing transformative shifts driven by converging forces in science, consumer preferences, and channel economics. Advances in clinical understanding of vitamin D’s roles have intensified demand for evidence-backed formulations, prompting manufacturers to reassess ingredient sourcing, dosage transparency, and claims substantiation. At the same time, consumer preferences have migrated toward formats that blend convenience with perceived naturalness, fueling innovation in softgels, chewables, and pectin-based gummy options that accommodate vegetarian and clean-label expectations.
Concurrently, distribution is fragmenting: direct-to-consumer platforms and marketplace ecosystems are complementing traditional pharmacy and specialty retail channels, enabling brands to accelerate feedback loops and refine personalization strategies. Supply chain resilience and ingredient traceability have become differentiators as buyers and retailers place premium value on provenance and quality assurance. These shifts collectively favor firms that can integrate robust clinical communication, agile manufacturing, and omnichannel marketing to meet evolving consumer and trade partner expectations.
The 2025 tariff adjustments and their strategic ripple effects across sourcing, contract manufacturing, logistics, and procurement playbooks in the vitamin D value chain
Tariff policy adjustments implemented in 2025 have introduced a layer of complexity to sourcing and cost management for companies operating in the vitamin D supplements space, particularly for firms with cross-border ingredient flows and finished-product imports. These tariff adjustments have prompted procurement teams to re-evaluate supplier footprints and to accelerate qualification of alternate suppliers in lower-tariff jurisdictions, while procurement playbooks increasingly emphasize total landed cost and duty mitigation strategies rather than unit price alone.
As a result, supply chain planners have adopted diversified sourcing models to reduce exposure to single-country tariffs and to create redundancy in ingredient supply, especially for raw materials that are concentrated geographically. Manufacturers have also intensified contract negotiations with logistics providers and customs specialists to identify classification strategies and preferential trade program eligibility where appropriate. Over time, these tactical responses are encouraging longer-term structural decisions such as regional manufacturing capacity enhancements and strategic partnerships with local contract manufacturers to preserve margin and continuity of supply.
Deep segmentation intelligence across ingredient selection, diverse product formats, consumer cohorts, application narratives, and channel pathways to inform targeted portfolio strategies
Segmentation insighting reveals that ingredient source, form, end user, application, and distribution pathways each present distinct commercial levers and risk vectors that companies must integrate into product and channel strategies. Considering ingredient source, choices between cholecalciferol and ergocalciferol have implications for bioavailability claims, labeling strategy, and regulatory risk management, and these considerations must feed into formulation and positioning decisions. In terms of delivery format, the product mix that encompasses capsules, gummies, liquids, powders, softgels, and tablets is diversifying: gummies have become a focal innovation space with gelatin and pectin variants addressing both traditional and plant-based consumer segments, while liquids and powders enable multi-ingredient and high-dose applications that appeal to specific subpopulations.
End-user segmentation-adult, athlete, child, pregnant women, and senior-necessitates tailored dosing, safety messaging, and compliance considerations, with athletes and seniors often requiring targeted formulations aligned to recovery, performance, or bone health priorities. Application-based differentiation between bone health, general health, and immune support underscores the need for distinct clinical narratives; within general health, the split between health maintenance and wellness underscores marketing differentiation between preventive care positioning and lifestyle-oriented wellness. Distribution channels ranging from online retail to pharmacy, specialty store, and supermarket each influence packaging decisions, regulatory claims presentation, and promotional cadence, and the nuances within online retail-direct brand websites versus broad marketplaces-create divergent strategies for pricing, advertising investment, and customer data capture. Integrating these segmentation lenses enables companies to design portfolios that are both commercially coherent and operationally feasible.
Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that dictate differentiated product design, regulatory strategy, and channel prioritization
Regional dynamics continue to shape strategic priorities for manufacturers and distributors, with each geography presenting distinct regulatory, channel, and consumption characteristics that influence product development and go-to-market approaches. In the Americas, demand patterns emphasize functional benefits tied to preventative health and active lifestyles, with pharmacy and supermarket channels retaining strong prominence while online retail grows as an acquisition and subscription channel. Public health dialogues and clinician recommendations also drive product credibility expectations in this region.
Europe, Middle East & Africa exhibit heterogeneous regulatory frameworks and a strong emphasis on ingredient provenance and label transparency, prompting companies to navigate diverse registration requirements while leveraging specialty retail and pharmacy channels for trust-based distribution. Meanwhile, the Asia-Pacific region displays rapid format innovation and high receptivity to gummy and liquid formats, alongside robust online marketplace penetration and dynamic retail ecosystems. These regional distinctions compel firms to adopt differentiated product specifications, pricing strategies, and compliance roadmaps tailored to local consumer behaviors and regulatory expectations.
Competitive landscape insights revealing how legacy manufacturers, digital challengers, contract producers, and ingredient specialists are advancing distinct growth models and differentiation tactics
Competitive dynamics in the vitamin D supplements sector are defined by a mix of legacy supplement manufacturers, digitally native brands, contract manufacturers, and ingredient specialists each pursuing distinct routes to growth. Established manufacturers leverage scale, regulatory experience, and long-term retail relationships to maintain shelf presence and to invest in clinical substantiation, whereas digitally native brands are leveraging direct consumer relationships, targeted digital acquisition, and rapid product iteration to capture niche segments and build subscription revenue streams.
Contract manufacturers and private-label operators are responding to demand for faster time-to-market by expanding capabilities in small-batch, certified clean-label, and specialty format production, while ingredient suppliers are differentiating through traceability programs and third-party verification to support premium positioning. Across the competitor set, successful players demonstrate disciplined supply chain integration, a strong capability in scientific communication for claims support, and nimble commercialization models that align product form, dosage, and messaging with precise end-user cohorts. Strategic collaborations, selective licensing of clinical data, and investments in sustainable packaging are emerging tactics among leaders seeking to fortify their value propositions.
Actionable strategic priorities for leaders focusing on scientific integration, sourcing resilience, omnichannel optimization, and traceability to secure competitive advantage
Industry leaders should prioritize an integrated approach that aligns scientific credibility, supply chain resilience, and consumer-centric innovation to capture both near-term opportunities and long-term trust. First, embed clinical and regulatory teams early in the product development lifecycle to ensure that formulation choices-such as ingredient variant and dose-are defensible and can be communicated clearly to clinicians, regulators, and consumers. Doing so reduces downstream compliance risk and strengthens shelf negotiation with pharmacists and retailers.
Second, invest in multi-sourcing and regional manufacturing options to insulate operations from tariff volatility and logistics disruptions; closely align contract manufacturing partnerships to enable rapid format shifts, including expansions into pectin-based gummy production and liquid or powder formats for specialty applications. Third, build differentiated omnichannel strategies: leverage brand websites for data capture and direct engagement while optimizing marketplace presence for reach, and tailor promotional investments according to channel economics rather than a one-size-fits-all approach. Lastly, pursue traceability and sustainability initiatives that support premium positioning and meet growing retail and consumer expectations for provenance, which in turn enhance long-term brand equity and price resilience.
A rigorous mixed-methods research approach combining interviews, supply chain mapping, regulatory analysis, and literature review to produce validated, actionable intelligence
The research adopted a mixed-methods approach combining primary interviews, supply chain tracing, regulatory review, and secondary literature analysis to ensure findings are grounded in both qualitative insight and documented evidence. Primary engagement included structured interviews with procurement leaders, R&D heads, and channel managers to surface operational challenges and strategic responses; these conversations were triangulated with publicly available regulatory guidance and trade documentation to validate compliance timelines and classification considerations.
Supply chain mapping exercises traced ingredient flows and logistics touchpoints to illuminate vulnerability points and opportunities for regionalization. Secondary analysis of industry publications and scientific literature provided context for clinical positioning and consumer behavior trends, while internal cross-validation routines ensured consistency across data sources. The methodology emphasized transparency in assumptions, documented data provenance, and a bias toward actionable intelligence. Limitations included variability in regional regulatory interpretation and the evolving nature of tariff policy, which were addressed by scenario-based sensitivity checks and conservative framing of strategic implications.
Concluding synthesis that connects scientific credibility, manufacturing flexibility, and channel strategy into an integrated blueprint for durable competitive advantage in vitamin D supplements
In conclusion, the vitamin D supplements landscape is in a phase of pragmatic transformation where scientific substantiation, format innovation, and supply chain strategy jointly determine commercial success. Companies that proactively integrate clinical rigor with flexible manufacturing and channel-aware commercialization will be better positioned to meet shifting consumer expectations and to absorb policy and trade shocks. The strategic imperative is clear: align product design and communication to distinct end-user needs while building sourcing and distribution architectures that protect continuity and enable growth.
Moving forward, leaders should treat these dynamics as interconnected rather than isolated priorities; investments in traceability and clinical support enhance both consumer trust and retailer relationships, while regional manufacturing and diversified channels reduce exposure to tariff-driven disruption. By synthesizing operational resilience with differentiated product narratives, organizations can convert current challenges into durable competitive advantage.
Note: PDF & Excel + Online Access - 1 Year
A concise integrated overview of supply chain, consumer dynamics, regulatory shifts, and product innovation shaping strategic planning for vitamin D supplements
This executive summary synthesizes contemporary dynamics shaping the vitamin D supplements landscape to equip senior leaders with contextually relevant intelligence and actionable perspective. It draws together supply chain trends, regulatory developments, consumer behavior shifts, and distribution innovations that converge to influence product development, go-to-market approaches, and procurement priorities. The aim is to provide a succinct, integrated briefing that supports cross-functional planning across R&D, commercial strategy, and operations.
The narrative foregrounds the interplay of scientific validation, ingredient sourcing decisions, and evolving consumption formats, while recognizing the importance of regulatory clarity and trade flows. By emphasizing implications rather than raw metrics, the summary anticipates near-term strategic choices and highlights priority areas for deeper analysis. Readers should be able to translate the insights into concrete next steps for portfolio refinement, channel optimization, and stakeholder engagement.
How scientific validation, consumer preference evolution, and omnichannel distribution convergence are reshaping product formulation and go-to-market approaches in vitamin D supplements
The vitamin D supplements arena is undergoing transformative shifts driven by converging forces in science, consumer preferences, and channel economics. Advances in clinical understanding of vitamin D’s roles have intensified demand for evidence-backed formulations, prompting manufacturers to reassess ingredient sourcing, dosage transparency, and claims substantiation. At the same time, consumer preferences have migrated toward formats that blend convenience with perceived naturalness, fueling innovation in softgels, chewables, and pectin-based gummy options that accommodate vegetarian and clean-label expectations.
Concurrently, distribution is fragmenting: direct-to-consumer platforms and marketplace ecosystems are complementing traditional pharmacy and specialty retail channels, enabling brands to accelerate feedback loops and refine personalization strategies. Supply chain resilience and ingredient traceability have become differentiators as buyers and retailers place premium value on provenance and quality assurance. These shifts collectively favor firms that can integrate robust clinical communication, agile manufacturing, and omnichannel marketing to meet evolving consumer and trade partner expectations.
The 2025 tariff adjustments and their strategic ripple effects across sourcing, contract manufacturing, logistics, and procurement playbooks in the vitamin D value chain
Tariff policy adjustments implemented in 2025 have introduced a layer of complexity to sourcing and cost management for companies operating in the vitamin D supplements space, particularly for firms with cross-border ingredient flows and finished-product imports. These tariff adjustments have prompted procurement teams to re-evaluate supplier footprints and to accelerate qualification of alternate suppliers in lower-tariff jurisdictions, while procurement playbooks increasingly emphasize total landed cost and duty mitigation strategies rather than unit price alone.
As a result, supply chain planners have adopted diversified sourcing models to reduce exposure to single-country tariffs and to create redundancy in ingredient supply, especially for raw materials that are concentrated geographically. Manufacturers have also intensified contract negotiations with logistics providers and customs specialists to identify classification strategies and preferential trade program eligibility where appropriate. Over time, these tactical responses are encouraging longer-term structural decisions such as regional manufacturing capacity enhancements and strategic partnerships with local contract manufacturers to preserve margin and continuity of supply.
Deep segmentation intelligence across ingredient selection, diverse product formats, consumer cohorts, application narratives, and channel pathways to inform targeted portfolio strategies
Segmentation insighting reveals that ingredient source, form, end user, application, and distribution pathways each present distinct commercial levers and risk vectors that companies must integrate into product and channel strategies. Considering ingredient source, choices between cholecalciferol and ergocalciferol have implications for bioavailability claims, labeling strategy, and regulatory risk management, and these considerations must feed into formulation and positioning decisions. In terms of delivery format, the product mix that encompasses capsules, gummies, liquids, powders, softgels, and tablets is diversifying: gummies have become a focal innovation space with gelatin and pectin variants addressing both traditional and plant-based consumer segments, while liquids and powders enable multi-ingredient and high-dose applications that appeal to specific subpopulations.
End-user segmentation-adult, athlete, child, pregnant women, and senior-necessitates tailored dosing, safety messaging, and compliance considerations, with athletes and seniors often requiring targeted formulations aligned to recovery, performance, or bone health priorities. Application-based differentiation between bone health, general health, and immune support underscores the need for distinct clinical narratives; within general health, the split between health maintenance and wellness underscores marketing differentiation between preventive care positioning and lifestyle-oriented wellness. Distribution channels ranging from online retail to pharmacy, specialty store, and supermarket each influence packaging decisions, regulatory claims presentation, and promotional cadence, and the nuances within online retail-direct brand websites versus broad marketplaces-create divergent strategies for pricing, advertising investment, and customer data capture. Integrating these segmentation lenses enables companies to design portfolios that are both commercially coherent and operationally feasible.
Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that dictate differentiated product design, regulatory strategy, and channel prioritization
Regional dynamics continue to shape strategic priorities for manufacturers and distributors, with each geography presenting distinct regulatory, channel, and consumption characteristics that influence product development and go-to-market approaches. In the Americas, demand patterns emphasize functional benefits tied to preventative health and active lifestyles, with pharmacy and supermarket channels retaining strong prominence while online retail grows as an acquisition and subscription channel. Public health dialogues and clinician recommendations also drive product credibility expectations in this region.
Europe, Middle East & Africa exhibit heterogeneous regulatory frameworks and a strong emphasis on ingredient provenance and label transparency, prompting companies to navigate diverse registration requirements while leveraging specialty retail and pharmacy channels for trust-based distribution. Meanwhile, the Asia-Pacific region displays rapid format innovation and high receptivity to gummy and liquid formats, alongside robust online marketplace penetration and dynamic retail ecosystems. These regional distinctions compel firms to adopt differentiated product specifications, pricing strategies, and compliance roadmaps tailored to local consumer behaviors and regulatory expectations.
Competitive landscape insights revealing how legacy manufacturers, digital challengers, contract producers, and ingredient specialists are advancing distinct growth models and differentiation tactics
Competitive dynamics in the vitamin D supplements sector are defined by a mix of legacy supplement manufacturers, digitally native brands, contract manufacturers, and ingredient specialists each pursuing distinct routes to growth. Established manufacturers leverage scale, regulatory experience, and long-term retail relationships to maintain shelf presence and to invest in clinical substantiation, whereas digitally native brands are leveraging direct consumer relationships, targeted digital acquisition, and rapid product iteration to capture niche segments and build subscription revenue streams.
Contract manufacturers and private-label operators are responding to demand for faster time-to-market by expanding capabilities in small-batch, certified clean-label, and specialty format production, while ingredient suppliers are differentiating through traceability programs and third-party verification to support premium positioning. Across the competitor set, successful players demonstrate disciplined supply chain integration, a strong capability in scientific communication for claims support, and nimble commercialization models that align product form, dosage, and messaging with precise end-user cohorts. Strategic collaborations, selective licensing of clinical data, and investments in sustainable packaging are emerging tactics among leaders seeking to fortify their value propositions.
Actionable strategic priorities for leaders focusing on scientific integration, sourcing resilience, omnichannel optimization, and traceability to secure competitive advantage
Industry leaders should prioritize an integrated approach that aligns scientific credibility, supply chain resilience, and consumer-centric innovation to capture both near-term opportunities and long-term trust. First, embed clinical and regulatory teams early in the product development lifecycle to ensure that formulation choices-such as ingredient variant and dose-are defensible and can be communicated clearly to clinicians, regulators, and consumers. Doing so reduces downstream compliance risk and strengthens shelf negotiation with pharmacists and retailers.
Second, invest in multi-sourcing and regional manufacturing options to insulate operations from tariff volatility and logistics disruptions; closely align contract manufacturing partnerships to enable rapid format shifts, including expansions into pectin-based gummy production and liquid or powder formats for specialty applications. Third, build differentiated omnichannel strategies: leverage brand websites for data capture and direct engagement while optimizing marketplace presence for reach, and tailor promotional investments according to channel economics rather than a one-size-fits-all approach. Lastly, pursue traceability and sustainability initiatives that support premium positioning and meet growing retail and consumer expectations for provenance, which in turn enhance long-term brand equity and price resilience.
A rigorous mixed-methods research approach combining interviews, supply chain mapping, regulatory analysis, and literature review to produce validated, actionable intelligence
The research adopted a mixed-methods approach combining primary interviews, supply chain tracing, regulatory review, and secondary literature analysis to ensure findings are grounded in both qualitative insight and documented evidence. Primary engagement included structured interviews with procurement leaders, R&D heads, and channel managers to surface operational challenges and strategic responses; these conversations were triangulated with publicly available regulatory guidance and trade documentation to validate compliance timelines and classification considerations.
Supply chain mapping exercises traced ingredient flows and logistics touchpoints to illuminate vulnerability points and opportunities for regionalization. Secondary analysis of industry publications and scientific literature provided context for clinical positioning and consumer behavior trends, while internal cross-validation routines ensured consistency across data sources. The methodology emphasized transparency in assumptions, documented data provenance, and a bias toward actionable intelligence. Limitations included variability in regional regulatory interpretation and the evolving nature of tariff policy, which were addressed by scenario-based sensitivity checks and conservative framing of strategic implications.
Concluding synthesis that connects scientific credibility, manufacturing flexibility, and channel strategy into an integrated blueprint for durable competitive advantage in vitamin D supplements
In conclusion, the vitamin D supplements landscape is in a phase of pragmatic transformation where scientific substantiation, format innovation, and supply chain strategy jointly determine commercial success. Companies that proactively integrate clinical rigor with flexible manufacturing and channel-aware commercialization will be better positioned to meet shifting consumer expectations and to absorb policy and trade shocks. The strategic imperative is clear: align product design and communication to distinct end-user needs while building sourcing and distribution architectures that protect continuity and enable growth.
Moving forward, leaders should treat these dynamics as interconnected rather than isolated priorities; investments in traceability and clinical support enhance both consumer trust and retailer relationships, while regional manufacturing and diversified channels reduce exposure to tariff-driven disruption. By synthesizing operational resilience with differentiated product narratives, organizations can convert current challenges into durable competitive advantage.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
189 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growing popularity of vegan and plant-based vitamin D sources in response to clean label demands
- 5.2. Integration of vitamin D fortification into staple food products to address public health deficiencies
- 5.3. Emergence of high-potency vitamin D microdosing supplements targeting optimal blood concentration levels
- 5.4. Increasing investment in vitamin D nanoemulsion technology to improve absorption and bioavailability
- 5.5. Rising adoption of subscription-based digital health platforms offering customized vitamin D dosing
- 5.6. Development of dual-action supplements combining vitamin D with immune-modulating botanicals
- 5.7. Regulatory scrutiny intensifying around maximum vitamin D dosage labeling and safety guidelines
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Vitamin D Supplements Market, by Ingredient Source
- 8.1. Cholecalciferol
- 8.2. Ergocalciferol
- 9. Vitamin D Supplements Market, by Form
- 9.1. Capsule
- 9.2. Gummy
- 9.2.1. Gelatin
- 9.2.2. Pectin
- 9.3. Liquid
- 9.4. Powder
- 9.5. Softgel
- 9.6. Tablet
- 10. Vitamin D Supplements Market, by End User
- 10.1. Adult
- 10.2. Athlete
- 10.3. Child
- 10.4. Pregnant Women
- 10.5. Senior
- 11. Vitamin D Supplements Market, by Application
- 11.1. Bone Health
- 11.2. General Health
- 11.2.1. Health Maintenance
- 11.2.2. Wellness
- 11.3. Immune Support
- 12. Vitamin D Supplements Market, by Distribution Channel
- 12.1. Online Retail
- 12.1.1. Brand Website
- 12.1.2. Marketplace
- 12.2. Pharmacy
- 12.3. Specialty Store
- 12.4. Supermarket
- 13. Vitamin D Supplements Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Vitamin D Supplements Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Vitamin D Supplements Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Pfizer Inc.
- 16.3.2. Nature's Bounty Co.
- 16.3.3. NOW Foods Inc.
- 16.3.4. Solgar Inc.
- 16.3.5. Garden of Life LLC
- 16.3.6. MegaFood Inc.
- 16.3.7. Jarrow Formulas Inc.
- 16.3.8. Nordic Naturals Inc.
- 16.3.9. Carlson Labs
- 16.3.10. Doctor's Best Inc.
- 16.3.11. Pure Encapsulations LLC
- 16.3.12. Swanson Health Products Inc.
- 16.3.13. Nature's Way Products LLC
- 16.3.14. SmartyPants Vitamins Inc.
- 16.3.15. Life Extension Foundation
- 16.3.16. Bluebonnet Nutrition Corp.
- 16.3.17. Rainbow Light Nutritional Systems Inc.
- 16.3.18. New Chapter Inc.
- 16.3.19. Zahler Inc.
- 16.3.20. Ortho Molecular Products Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
